Re-treatment with immune checkpoint inhibitors in kidney cancer patients

Immune checkpoint inhibitor combinations for the treatment of patients with metastatic renal cell carcinoma (RCC) have shown considerable promise. However, disease progression is inevitable for most patients. A recent review article published in Nature Reviews Clinical Oncology summarises the results of re-treatment with immune checkpoint inhibitors. Two retrospective studies investigated the safety and efficacy of […]

read more
Showing the single result
  TOP